Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Tests to Determine Best Chemotherapy

By MedImaging staff writers
Posted on 07 Feb 2005
By combining two methods for evaluating the effectiveness of anticancer chemotherapy, researchers have developed a rapid and sensitive system for selecting the most appropriate drug for an individual patient.

Investigators at the Yale School of Medicine (New Haven, CT, USA) have combined their apoptosis assay with the commercially available ChemoFX assay offered by Precision Therapeutics, Inc. More...
(Pittsburgh, PA, USA).

The ChemoFX assay determines whether a drug will stop tumor growth. Tumor cells are removed during a surgical or biopsy procedure, and the tumor-derived cells are grown in tissue culture. The cells are then treated with anticancer drugs, and the amount of tumor-derived cells killed by each drug is determined. The Yale apoptosis assay measures the ability of the drug to stimulate the process of cell death.

"These two new assays will take the guesswork out of cancer treatment,” explained Dr. Gil Mor, associate professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine. "In patients with very limited time left to live, six months can feel like an eternity when they may have to start a whole new course of treatment if it proves ineffective. This test will help physicians predict whether a patient will respond to a specific drug, much like they test bacteria for sensitivity to antibiotics.”




Related Links:
Yale School of Medicine
Precision Therapeutics, Inc.

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.